Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PTAFR | P25105 | 2/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46283 | 0.82 | TSHR (0.67) | TSHRPARP1GSTO1ADRA2ACHRM2 | |
| SCHEMBL14753778 | 0.80 | TSHR (0.39) | TSHRPARP1GSTO1CHRM2CHRM4 | |
| SCHEMBL11408352 | 0.80 | TSHR (0.44) | TSHRPARP1CHRM2CHRM4CHRM1 | |
| SCHEMBL16413144 | 0.80 | TSHR (0.44) | TSHRPARP1GSTO1CHRM2CHRM4 | |
| SCHEMBL18993098 | 0.80 | TSHR (0.44) | TSHRPARP1GSTO1 | |
| SCHEMBL6301377 | 0.80 | TSHR (0.44) | TSHRPARP1GSTO1 | |
| SCHEMBL7053297 | 0.80 | TSHR (0.44) | TSHRPARP1GSTO1 | |
| SCHEMBL17334003 | 0.78 | TSHR (0.48) | TSHRPARP1GSTO1ADRA2ACHRM2 | |
| SCHEMBL7053649 | 0.78 | TSHR (0.42) | TSHRPARP1GSTO1 | |
| SCHEMBL532105 | 0.74 | HTR1A (0.40) | TSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144733-A1 | HEXASUBSTITUTED BENZENES, SURFACES MODIFIED THEREWITH, AND ASSOCIATED METHODS | Countertrace, LLC (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144733-A1 | HEXASUBSTITUTED BENZENES, SURFACES MODIFIED THEREWITH, AND ASSOCIATED METHODS | CBR3, BRD3, CBX3 | TSHR 654/4885PARP1 2262/4885GSTO1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.